Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Rhea-AI Summary
Nexalin Technology (Nasdaq: NXL) has received a Notice of Allowance from the USPTO for a patent covering its Deep Intracranial Frequency Stimulation (DIFS™) technology for treating substance use disorders. The patent, titled 'Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD),' encompasses treatment for opioid, alcohol, cocaine, and methamphetamine use disorders.
The DIFS™ technology represents a non-invasive, drug-free approach that aims to modulate neural pathways associated with addiction and withdrawal symptoms. This technology could offer an alternative to traditional medication-assisted treatment (MAT) and behavioral therapy, potentially avoiding their associated challenges like accessibility issues and side effects.
Positive
- Secured USPTO patent allowance strengthening intellectual property portfolio
- Technology offers potential alternative to traditional addiction treatments
- Expands addressable market to multiple substance use disorders
Negative
- Technology still in development phase with unproven efficacy
- No mention of clinical trial results or regulatory approvals
- Faces competition from established treatment methods
News Market Reaction – NXL
In the trading session that priced this news, NXL declined 10.70%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and Methamphetamine
HOUSTON, TX, March 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled “Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD).”
This newly allowed patent covers Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, a non-invasive, drug-free approach designed to support individuals struggling with substance use disorder (SUD), including opioid use disorder (OUD), alcohol use disorder (AUD), and stimulant addiction, such as cocaine and methamphetamine use disorders. By delivering deep-brain stimulation at dynamic frequencies, DIFS technology has the potential to modulate neural pathways associated with addiction and withdrawal symptoms, offering a novel treatment pathway for those affected by various forms of substance dependence.
Mark White, CEO of Nexalin Technology, commented, “Receiving this Notice of Allowance from the USPTO is a major step in Nexalin’s ongoing mission to provide innovative, non-invasive solutions for some of the most urgent healthcare challenges. Substance use disorders continue to devastate families and communities worldwide, and we believe our DIFS technology has the potential to play a transformative role in improving treatment outcomes. This patent further expands our intellectual property portfolio and reinforces Nexalin’s position as a leader in advancing groundbreaking medical technology.”
Substance use disorders, including opioid addiction, alcoholism, and stimulant dependence remain significant public health emergencies, affecting millions of individuals worldwide. While medication-assisted treatment (MAT) and behavioral therapy remain standard approaches, they present challenges related to accessibility, reliance on pharmaceuticals, and potential side effects. Nexalin’s DIFS technology offers a drug-free, non-invasive alternative that may help ease withdrawal symptoms and support long-term recovery without the risks associated with traditional treatment options.
David Owens, CMO of Nexalin Technology, stated, “Substance use disorders represent one of the most pressing public health crises of our time. Nexalin is committed to advancing new solutions that address critical unmet medical needs. Our proprietary DIFS technology is designed to deliver precise, deep-brain stimulation without the use of drugs or invasive procedures, representing a potential paradigm shift in addiction treatment. With this newly allowed patent, we are further establishing Nexalin as a leader in pioneering non-invasive treatment solutions for neurological and mental health conditions.”
This latest patent builds upon Nexalin’s expanding intellectual property portfolio, which includes cutting-edge advancements in non-invasive brain stimulation for mental health, addiction, and neurological disorders. As Nexalin continues to develop next-generation solutions, the Company remains committed to providing breakthrough technologies that improve patient outcomes and redefine standards of care in mental health and addiction treatment.
For more information about Nexalin Technology and its innovative medical technology solutions, visit www.nexalin-usa.com.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
Forward-looking statements
This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
